Formations of, Acquisitions by, and Mergers of Bank Holding Companies, 45765 [2019-18818]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 169 / Friday, August 30, 2019 / Notices
Board of Governors of the Federal Reserve
System, August 27, 2019.
Yao-Chin Chao,
Assistant Secretary of the Board.
FEDERAL RESERVE SYSTEM
jspears on DSK3GMQ082PROD with NOTICES
Formations of, Acquisitions by, and
Mergers of Bank Holding Companies
The companies listed in this notice
have applied to the Board for approval,
pursuant to the Bank Holding Company
Act of 1956 (12 U.S.C. 1841 et seq.)
(BHC Act), Regulation Y (12 CFR part
225), and all other applicable statutes
and regulations to become a bank
holding company and/or to acquire the
assets or the ownership of, control of, or
the power to vote shares of a bank or
bank holding company and all of the
banks and nonbanking companies
owned by the bank holding company,
including the companies listed below.
The applications listed below, as well
as other related filings required by the
Board, are available for immediate
inspection at the Federal Reserve Bank
indicated. The applications will also be
available for inspection at the offices of
the Board of Governors. Interested
persons may express their views in
writing on the standards enumerated in
the BHC Act (12 U.S.C. 1842(c)). If the
proposal also involves the acquisition of
a nonbanking company, the review also
includes whether the acquisition of the
nonbanking company complies with the
standards in section 4 of the BHC Act
(12 U.S.C. 1843). Unless otherwise
noted, nonbanking activities will be
conducted throughout the United States.
Unless otherwise noted, comments
regarding each of these applications
must be received at the Reserve Bank
indicated or the offices of the Board of
Governors not later than October 1,
2019.
A. Federal Reserve Bank of Atlanta
(Kathryn Haney, Assistant Vice
President) 1000 Peachtree Street NE,
Atlanta, Georgia 30309. Comments can
also be sent electronically to
Applications.Comments@atl.frb.org:
1. IFB Bancorp, Inc., Miami, Florida;
to become a bank holding company by
acquiring 100 percent of the outstanding
shares of International Finance Bank,
Miami, Florida.
B. Federal Reserve Bank of St. Louis
(David L. Hubbard, Senior Manager)
P.O. Box 442, St. Louis, Missouri
63166–2034. Comments can also be sent
electronically to
Comments.applications@stls.frb.org:
1. King Harris Bancorp, Inc.,
Louisville, Kentucky; to become a bank
holding company by acquiring 89.77
percent of the voting shares of
Community Financial of Kentucky, Inc.,
and thereby indirectly acquiring Peoples
Bank, both of Lebanon, Kentucky.
VerDate Sep<11>2014
16:43 Aug 29, 2019
Jkt 247001
[FR Doc. 2019–18818 Filed 8–29–19; 8:45 am]
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
In accordance with the
Federal Advisory Committee Act, the
CDC announces the following meeting
for the Clinical Laboratory Improvement
Advisory Committee (CLIAC). This
meeting is open to the public, limited
only by the space available. The meeting
room accommodates approximately 250
people. The public is also welcome to
view the meeting by webcast. Check the
CLIAC website on the day of the
meeting for the webcast link
www.cdc.gov/cliac.
DATES: The meeting will be held on
November 6, 2019, 8:30 a.m. to 5:30
p.m., EST and November 7, 2019, 8:30
a.m. to 12:00 p.m., EST.
ADDRESSES: CDC, 1600 Clifton Road NE,
Tom Harkin Global Communications
Center, Building 19, Auditorium B,
Atlanta, Georgia 30329–4027 and via
webcast at www.cdc.gov/cliac.
FOR FURTHER INFORMATION CONTACT:
Nancy Anderson, MMSc, MT(ASCP),
Senior Advisor for Clinical Laboratories,
Division of Laboratory Systems, Center
for Surveillance, Epidemiology and
Laboratory Services, Office of Public
Health Scientific Services, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, Mailstop V24–3,
Atlanta, Georgia 30329–4027, telephone
(404) 498–2741; NAnderson@cdc.gov.
SUPPLEMENTARY INFORMATION:
Purpose: This Committee is charged
with providing scientific and technical
advice and guidance to the Secretary of
Health and Human Services (HHS); the
Assistant Secretary for Health; the
Director, Centers for Disease Control
and Prevention; the Commissioner,
Food and Drug Administration (FDA);
and the Administrator, Centers for
Medicare and Medicaid Services (CMS).
The advice and guidance pertain to
general issues related to improvement in
SUMMARY:
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
45765
clinical laboratory quality and
laboratory medicine practice and
specific questions related to possible
revision of the Clinical Laboratory
Improvement Amendment (CLIA)
standards. Examples include providing
guidance on studies designed to
improve safety, effectiveness, efficiency,
timeliness, equity, and patientcenteredness of laboratory services;
revisions to the standards under which
clinical laboratories are regulated; the
impact of proposed revisions to the
standards on medical and laboratory
practice; and the modification of the
standards and provision of nonregulatory guidelines to accommodate
technological advances, such as new
test methods, the electronic
transmission of laboratory information,
and mechanisms to improve the
integration of public health and clinical
laboratory practices.
All people attending the CLIAC
meeting in-person are required to
register for the meeting online at least
five business days in advance for U.S.
citizens and at least 15 business days in
advance for international registrants.
Register at: www.cdc.gov/cliac. Register
by scrolling down and clicking the
‘‘Register for this Meeting’’ button and
completing all forms according to the
instructions given. Please complete all
the required fields before submitting
your registration and submit no later
than October 29, 2019 for U.S.
registrants and October 15, 2019 for
international registrants.
It is the policy of CLIAC to accept
written public comments and provide a
brief period for oral public comments on
agenda items. Public comment periods
for each agenda item are scheduled
immediately prior to the Committee
discussion period for that item. At this
meeting, CLIAC is specifically soliciting
public comments to address the
questions below. Information provided
via public comments will not be
considered advice directly addressed to
HHS. Rather, it will be used by CLIAC
to inform their deliberations and
recommendations to HHS and to help
focus a CLIAC workgroup that will be
convened in response to an April 2019
CLIAC recommendation that such a
workgroup be charged with providing
input to CLIAC in advising how CLIA
might be updated.
1. Are bioinformaticists needed in
clinical and public health laboratories?
If so, what are the current roles,
responsibilities, and competencies of
bioinformaticists in these settings?
2. What areas exist in CLIA where
specific requirements or guidance might
be needed to ensure the accuracy and
reliability of new and emerging
E:\FR\FM\30AUN1.SGM
30AUN1
]]>Agencies
[Federal Register Volume 84, Number 169 (Friday, August 30, 2019)]
[Notices]
[Page 45765]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-18818]
[[Page 45765]]
=======================================================================
-----------------------------------------------------------------------
FEDERAL RESERVE SYSTEM
Formations of, Acquisitions by, and Mergers of Bank Holding
Companies
The companies listed in this notice have applied to the Board for
approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C.
1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other
applicable statutes and regulations to become a bank holding company
and/or to acquire the assets or the ownership of, control of, or the
power to vote shares of a bank or bank holding company and all of the
banks and nonbanking companies owned by the bank holding company,
including the companies listed below.
The applications listed below, as well as other related filings
required by the Board, are available for immediate inspection at the
Federal Reserve Bank indicated. The applications will also be available
for inspection at the offices of the Board of Governors. Interested
persons may express their views in writing on the standards enumerated
in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the
acquisition of a nonbanking company, the review also includes whether
the acquisition of the nonbanking company complies with the standards
in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted,
nonbanking activities will be conducted throughout the United States.
Unless otherwise noted, comments regarding each of these
applications must be received at the Reserve Bank indicated or the
offices of the Board of Governors not later than October 1, 2019.
A. Federal Reserve Bank of Atlanta (Kathryn Haney, Assistant Vice
President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments
can also be sent electronically to [email protected]:
1. IFB Bancorp, Inc., Miami, Florida; to become a bank holding
company by acquiring 100 percent of the outstanding shares of
International Finance Bank, Miami, Florida.
B. Federal Reserve Bank of St. Louis (David L. Hubbard, Senior
Manager) P.O. Box 442, St. Louis, Missouri 63166-2034. Comments can
also be sent electronically to [email protected]:
1. King Harris Bancorp, Inc., Louisville, Kentucky; to become a
bank holding company by acquiring 89.77 percent of the voting shares of
Community Financial of Kentucky, Inc., and thereby indirectly acquiring
Peoples Bank, both of Lebanon, Kentucky.
Board of Governors of the Federal Reserve System, August 27,
2019.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2019-18818 Filed 8-29-19; 8:45 am]
BILLING CODE P
